Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Essential Thrombocytosis: early-phase trial registry
1 of 3 indexed Essential Thrombocytosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Essential Thrombocytosis: 3 US clinical trials tracked, 1 recruiting.
Essential Thrombocytosis is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Cephalon, running 1 of these trials.
Enrollment posture brief
Registry condition essential-thrombocytosis
OPEN 1 | RECR 33% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Essential Thrombocytosis lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Essential Thrombocytosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Essential Thrombocytosis is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Fox Chase Cancer Center
NCT06218628
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Cephalon
NCT00586651
Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
National Institutes of Health Clinical Center (CC)
NCT00433862
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Essential Thrombocytosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Essential Thrombocytosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Essential Thrombocytosis page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Essential Thrombocytosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Cephalon sponsors the most Essential Thrombocytosis trials on record, review their full trial history before evaluating a specific study. See Cephalon's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Essential Thrombocytosis condition card totals 3 registered trials; most-linked intervention lestaurtinib; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.